NASDAQ:VKTX的維京治療公司在週三收盤後公佈了其第四季度財務業績。以下是報告中的詳細信息。 維京治療公司報告季度每股虧損32美分，未達到分析師預期的每股虧損28美分。去年同期公司每股虧損爲25美分。 維京報告稱，第四季度淨虧損爲3540萬美元，而2023年同期的淨虧損爲2460萬美元。 截至2024年12月31日的一年中，研究與開發費用爲1.016億美元，而2023年同期爲6380萬美元。這一增長主要是由於藥物候選產品的製造費用、基於股票的補償和工資福利增加，部分被臨牀和臨牀前研究費用的減少所抵消。 維京首席執行官Brian Lian博士表示：“2024年是維京激動人心且極具成效的一年。公司在四個不同的臨牀試驗中報告了積極數據，包括用於肥胖的皮下注射VK2735的二期VENTURE研究、用於肥胖的口服VK2735的一期研究、用於治療MASH和纖維化的VK2809的二期VOYAGE研究以及用於X-ALD的VK0214的一期研究。每個研究都成功達到了其目標，並在我們看來展示了同類中最好的數據。” 根據Benzinga Pro的數據，維京治療公司股價在週三盤後下跌8.72%，至每股30.58美元。 圖片來源：T. Schneider via Shutterstock

以上內容來自Benzinga Earnings專欄，原文如下：

Viking Therapeutics, Inc. (NASDAQ:VKTX) annnounced its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the details from the report. 

The Details: Viking Therapeutics reported quarterly losses of 32 cents per share, which missed the analyst consensus estimate for losses of 28 cents. The company reported losses of 25 cents per share in the same period last year.

Viking reported a net loss of $35.4 million in the fourth quarter, compared to a net loss of $24.6 million, in the corresponding period in 2023.

Research and development expenses for the year ended Dec. 31, 2024, were $101.6 million compared to $63.8 million for the same period in 2023. The increase was primarily due to increased expenses related to manufacturing for drug candidates, stock-based compensation and salaries and benefits, partially offset by a decrease in expenses related to clinical studies and preclinical studies.

Read Next: Ford Shares Skid After Q4 Report: Details

“2024 was an exciting and extremely productive year for Viking,” stated Brian Lian, Ph.D., CEO of Viking.

“During the year, the company reported positive data from four different clinical trials, including results from the Phase 2 VENTURE study of subcutaneous VK2735 for obesity, the Phase 1 study of an oral tablet formulation of VK2735 for obesity, the Phase 2b VOYAGE study of VK2809 for the treatment of MASH and fibrosis, and the Phase 1b study of VK0214 for X-ALD. Each of these studies successfully achieved their objectives with each in our view demonstrating best-in-class data,” Lian said.

VKTX Price Action: According to data from Benzinga Pro, Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday.  

Read Next: 

• Robert F. Kennedy’s Health Secretary Nomination Advances To Full Senate: Vaccine Stocks Drop 

Photo: T. Schneider via Shutterstock